210 related articles for article (PubMed ID: 36525269)
21. Is Older Age a Real Adverse Prognostic Factor in Women With Early-Stage Endometrial Carcinoma? A Matched Analysis.
Haley L; Burmeister C; Buekers T; Elshaikh MA
Int J Gynecol Cancer; 2017 Mar; 27(3):479-485. PubMed ID: 28060139
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM
Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272
[TBL] [Abstract][Full Text] [Related]
23. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis.
Lax SF; Kurman RJ; Pizer ES; Wu L; Ronnett BM
Am J Surg Pathol; 2000 Sep; 24(9):1201-8. PubMed ID: 10976693
[TBL] [Abstract][Full Text] [Related]
24. Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.
Casanova J; Duarte GS; da Costa AG; Catarino A; Nave M; Antunes T; Serra SS; Dias SS; Abu-Rustum N; Lima J
Gynecol Oncol; 2024 Mar; 182():99-107. PubMed ID: 38262245
[TBL] [Abstract][Full Text] [Related]
25. Is the extent of lymphadenectomy a prognostic factor in International Federation of Gynecology and Obstetrics stage II endometrioid endometrial cancer?
Cuylan ZF; Akilli H; Gungorduk K; Demirkiran F; Oz M; Salman MC; Sozen H; Celik H; Gokcu M; Bese T; Meydanli MM; Ozgul N; Topuz S; Kuscu E; Kuru O; Gokmen S; Gultekin M; Ayhan A
J Obstet Gynaecol Res; 2021 Mar; 47(3):1134-1144. PubMed ID: 33426779
[TBL] [Abstract][Full Text] [Related]
26. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer.
Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410
[TBL] [Abstract][Full Text] [Related]
27. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
28. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
29. Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: a multicenter prospective cohort study.
Reijnen C; Visser NC; Kasius JC; Boll D; Geomini PM; Ngo H; Van Hamont D; Pijlman BM; Vos MC; Bulten J; Snijders MP; Massuger LF; Pijnenborg JM
J Gynecol Oncol; 2019 Sep; 30(5):e70. PubMed ID: 31328454
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
31. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
[TBL] [Abstract][Full Text] [Related]
32. Classification of high-grade endometrium carcinomas using molecular and immunohistochemical methods.
Bayramoglu D; Seçilmiş Kerimoğlu Ö; Bayramoğlu Z; Çintesun E; Şahin G; Karabağlı P; Çelik Ç
Ginekol Pol; 2023; 94(1):3-11. PubMed ID: 35072228
[TBL] [Abstract][Full Text] [Related]
33. Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.
Talhouk A; Jamieson A; Crosbie EJ; Taylor A; Chiu D; Leung S; Grube M; Kommoss S; Gilks CB; McAlpine JN; Singh N
Int J Gynecol Pathol; 2023 Jul; 42(4):353-363. PubMed ID: 36731023
[TBL] [Abstract][Full Text] [Related]
34. The impact of tumor grade on survival end points and patterns of recurrence of 949 patients with early-stage endometrioid carcinoma: a single institution study.
Gayar OH; Patel S; Schultz D; Mahan M; Rasool N; Elshaikh MA
Int J Gynecol Cancer; 2014 Jan; 24(1):97-101. PubMed ID: 24264358
[TBL] [Abstract][Full Text] [Related]
35. Ten years of experience with endometrial cancer treatment in a single Brazilian institution: Patient characteristics and outcomes.
Anton C; Kleine RT; Mayerhoff E; Diz MDPE; Freitas D; Carvalho HA; Carvalho JPM; Silva ASE; Genta MLND; Silva ALFE; Salim RC; Aranha A; Lopez RVM; Carvalho FM; Baracat EC; Carvalho JP
PLoS One; 2020; 15(3):e0229543. PubMed ID: 32134921
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic Association and Prognostic Value of Microcystic, Elongated, and Fragmented (MELF) Pattern in Endometrial Endometrioid Carcinoma.
Kihara A; Yoshida H; Watanabe R; Takahashi K; Kato T; Ino Y; Kitagawa M; Hiraoka N
Am J Surg Pathol; 2017 Jul; 41(7):896-905. PubMed ID: 28418994
[TBL] [Abstract][Full Text] [Related]
37. Differential impact of clinicopathological risk factors within the 2 largest ProMisE molecular subgroups of endometrial carcinoma.
Pasanen A; Loukovaara M; Ahvenainen T; Vahteristo P; Bützow R
PLoS One; 2021; 16(9):e0253472. PubMed ID: 34473724
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors and patterns of recurrence in lymphovascular space invasion positive women with stage IIIC endometriod endometrial cancer.
Cuylan ZF; Oz M; Ozkan NT; Comert GK; Sahin H; Turan T; Akbayir O; Kuscu E; Celik H; Dede M; Gungor T; Meydanli MM; Ayhan A
J Obstet Gynaecol Res; 2018 Jun; 44(6):1140-1149. PubMed ID: 29516573
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
40. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.
Han KH; Kim HS; Lee M; Chung HH; Song YS
Medicine (Baltimore); 2017 May; 96(21):e6976. PubMed ID: 28538399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
